Methods for reducing blood loss

• US 5,607,917 A
• Filed: 05/31/1995
• Issued: 03/04/1997
• Est. Priority Date: 12/31/1991
• Status: Expired due to Term

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Carter, Bruce L. A., Edwards, Martin W.
• Primary Examiner(s): Weimar, Elizabeth C.
• Assistant Examiner(s): TOUZEAU, LYNN
• Application Number:
  US08/456,018
• Time in Patent Office: 643 Days
• Field of Search: 530/381, 514/12
• US Class Current: 514/13.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61K 38/55 Protease inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Blood loss in a patient undergoing surgery, particularly thoracic or abdominal surgery, is reduced by administration of factor XIII. The factor XIII may be administered in combination with aprotinin.

Claims

1. A method of reducing perioperative blood loss in a patient undergoing surgery comprising administering to said patient an effective amount of factor XIII in a biologically compatible vehicle, wherein said factor XIII is substantially free of other blood coagulation factors and wherein said factor XIII is administered to said patient prior to or during said surgery, whereby perioperative blood loss by said patient is reduced.

2. The method of claim 1 wherein said factor XIII is administered prior to surgery as a bolus injection.

3. The method of claim 2 wherein said bolus injection of factor XIII is administered within one day prior to surgery.

4. The method of claim 1 wherein said factor XIII is administered at a dose of 0.1-1.0 mg per kg of patient weight.

5. The method of claim 1 wherein said factor XIII is administered at a dose of 0.15-0.4 mg per kg of patient weight.

6. The method of claim 1 wherein said factor XIII is factor XIII a₂ dimer.

7. The method of claim 1 wherein said factor XIII is recombinant factor XIII.

8. The method of claim 1 wherein said factor XIII is factor XIII zymogen.

9. The method of claim 1, further comprising administration of aprotinin to said patient.

10. The method of claim 9 wherein aprotinin is administered at a dose of 2×

10⁶ KIU to 8×

10⁶ KIU.

11. The method of claim 1 wherein said surgery is thoracic surgery.

12. A method of reducing perioperative blood loss in a patient undergoing surgery comprising administering to said patient a composition consisting essentially of factor XIII in a biologically compatible vehicle, wherein said factor XIII is administered to said patient prior to or during said surgery, whereby perioperative blood loss by said patient is reduced.